Karachi: Abbott Laboratories (Pakistan) Limited announced its financial results for the half year ending June 30, 2025, showing a significant increase in profitability compared to the previous year. The results were approved by the company’s Board of Directors in a meeting held on August 27, 2025.

The net sales for the six months ended June 30, 2025, reached 36.41 billion, a Very large or significant move from the 32.20 billion recorded during the same period in 2024. Local sales contributed substantially, with a figure of 34.91 billion, while export sales accounted for 1.49 billion. In comparison, for the three months ended June 30, 2025, net sales were reported at 19.06 billion, compared to 16.17 billion in the previous year, marking a Big move.

The cost of sales for the half year recorded a Minor move, amounting to 23.79 billion compared to 23.88 billion in the previous year. Consequently, the gross profit exhibited a Very large or significant move, increasing from 8.32 billion in 2024 to 12.61 billion in 2025.

Selling and distribution expenses saw a Big move, rising to 5.52 billion from 4.72 billion the previous year. Administrative expenses experienced a Minor move, registering at 638.20 million compared to 556.90 million in 2024. Other charges saw a Very large or significant move, climbing to 826.33 million from 308.40 million.

The company’s other income for the half year was 416.75 million, reflecting a Moderate move from the previous year’s 458.11 million. Despite increased expenses, Abbott Laboratories (Pakistan) Limited reported a profit before minimum tax differential and income tax of 6.00 billion, a Very large or significant move from 3.18 billion in 2024.

Profit before income tax also exhibited a Very large or significant move, standing at 6.00 billion, up from 3.02 billion in the previous year. After accounting for current and deferred income taxes, the profit for the period was 3.54 billion, marking a Very large or significant move from the 2.14 billion reported in 2024.

According to information available from the Pakistan Stock Exchange (PSX), Abbott Laboratories (Pakistan) Limited’s earnings per share for the period were 36.19, compared to 21.86 in the previous year, demonstrating a Very large or significant move in shareholder value.

The financial performance underscores the company’s robust operational efficiencies and strategic market positioning within the healthcare sector, contributing positively to its financial health and investor confidence.